Introduction {#S5}
============

Hypertension is an established major risk factor for an array of cardiovascular complications such as myocardial infarction or stroke, and is associated with a substantial increase in risk of premature death^[@C1]^. The great majority of hypertensive patients require drug treatment to control their condition, usually in the form of combinations with drugs of different mode of action and synergistic efficacy^[@C2]^. Current guidelines advise the use of combination therapy not only in second-line, but also in first-line therapy^[@C5]^. In addition, the ESH/ESC Guidelines recommend that in patients at higher risk, goal BP should be achieved promptly, which supports initial combination therapy and quicker adjustment of doses. Common clinical variables that influence prognosis should be used to stratify patient risk, including among others, higher age, abdominal obesity, diabetes mellitus (DM) or other metabolic risk factors.

The dihydropyridine calcium channel blocker (CCB) amlodipine, administered at doses of 5--10 mg once daily, is a direct peripheral arterial vasodilatator that reduces peripheral vascular resistance, and may reduce left ventricular hypertrophy^[@C8]^. The basis for approval of the single-pill combination (SPC) olmesartan/amlodipine (Sevikar), was formed by a factorial dose-finding study in patients with mild-to-moderate hypertension^[@C11]^, a long-term safety study^[@C12]^ and two randomized, double-blind studies in patients with moderate-to-severe hypertension who were not adequately treated on one component alone^[@C13],[@C14]^.

The direct renin inhibitor aliskiren inhibits the renin--angiotensin--aldosterone system at its rate-limiting step. Aliskiren was tested in patients with essential hypertension in a large development program as monotherapy or in double and triple combination with other classes of anti-hypertensive drugs^[@C15],[@C16]^. A number of studies with aliskiren investigated the drug in special patient groups (elderly, obese, components of the metabolic syndrome, see [Table 1](#TB1){ref-type="table"}).

###### 

Overview of studies with aliskiren in obese, elderly, or metabolic impaired patients.

  Author and references          Design                 Subgroup *n*   Duration (weeks)   Aliskiren schedule (mg/day)                Control drug schedule (mg/day)   ΔSBP/DBP vs. baseline in the aliskiren group (mmHg)   ΔSBP/DBP vs. baseline in the control group (mmHg)
  ------------------------------ ---------------------- -------------- ------------------ ------------------------------------------ -------------------------------- ----------------------------------------------------- ---------------------------------------------------
  **Obese (BMI ≥30)**                                                                                                                                                                                                       
   Schmieder^[@C37]^             r, pc, db, mc          396            12                 150 → 300                                  HCT 12.5 → 25                    16.7/12.3                                             12.2/9.1
                                                                       52                 +AMLO 5 → 10                               +AMLO 5 → 10                     19.9/15.5                                             17.6/13.3
   Jordan^[@C36]^                r, pc, db, mc          489            8                  HCT 25 + 150 → 300                         HCT 25 + irbesartan 150 → 300    15.8/11.9                                             15.4/11.3
                                                                       8                                                             HCT 25 + AMLO 5 → 10                                                                   13.6/10.3
                                                                       8                                                             HCT 25                                                                                 8.6/7.9
   Whaley-Conell^[@C38]^         r, c, db, mc           386            8                  150 → 300 + HCT 12.5 → 25                  Ramipril 5 → 10                  28.1/10.1                                             16.6/3.6
   Braun-Dullaeus^[@C39]^        r, c, db, mc           482            8                  150 → 300 + AMLO 5 → 10                    AMLO 5 → 10                      35.9/15.1                                             30.0/10.9
   Weir^[@C61]^                  Pooled meta-analysis   905            8--12              300                                        Placebo                          13.9/11.1                                             4.9/6.1
  **Elderly (aged 65+ years)**                                                                                                                                                                                              
   Verdecchia^[@C54]^            r, c, db, mc           355            8                  75                                         Lisinopril 10                    8.4/4.5                                               10.2/6.3
                                                                                          150                                                                         7.1/3.6                                               
                                                                                          300                                                                         8.7/3.9                                               
   Duprez^[@C55]^                r, c, db, mc           901            12                 150 → 300                                  Ramipril 5 → 10                  14.0/5.1                                              11.6/3.6
                                                                       22                 +HCT 12.5 → 25                             +HCT 12.5 → 25                   19.6/8.2                                              17.3/7.3
                                                                       36                 +HCT 12.5 → 25 + AMLO 5 → 10               +HCT 12.5 → 25 + AMLO 5 → 10     20.0/8.2                                              18.1/7.0
   Yarows^[@C61]^                r, pc, db, mc          1797           8                  150 → 300                                  Placebo                          14.5/8.6                                              5.1/5.3
                                                                                          +VAL 160 → 320                             VAL 160 → 320                    19.0/12.6                                             12.2/11.0
   Gradman^[@C62]^               Pooled                 704            8--12              150                                        Placebo                          13.4/11.7                                             4.4/8.1
                                                                                          300                                                                         14.9/12.3                                             
   Littlejohn^[@C63]^            o, mc                  101            54                 150 → 300 + AMLO 5 → 10 (+HCT 12.5 → 25)                                    30.4/17.6                                             
   Basile^[@C64]^                r, c, db, mc           54             8                  150 → 300 + HCT 12.5 → 25                                                   34.2/24.0                                             
   Schmieder^[@C56]^             o, prospective         7399           52                 150 → 300 ± other antihypertensive drug    ACEi/ARBs No ACEI/ARBs           19.6/7.6                                              15.5/6.3 16.3/6.6
                                                                                                                                     No ACEi/ARB                                                                            9.6/6.7
   Villa^[@C53]^                 r, pc, db              754            8                  75                                         Placebo                          13/5                                                  8/4
                                                                                          150                                                                         15/6                                                  
                                                                                          300                                                                         14/7                                                  
  **Diabetes mellitus**                                                                                                                                                                                                     
   Uresin^[@C47]^                r, c, mc               560            8                  150 → 300                                  Ramipril 5 → 10                  14.7/11.3                                             12.0/10.7
   Taylor^[@C49]^                Meta-analysis          1417           8--12              150                                        Placebo                          13.2/10.4                                             6.9/7.8
                                                                                          300                                        14.8/12.2                                                                              
   Townsend^[@C48]^              r, c, db, mc           860            8                  150 → 300 (+HCT 12.5 → 25)                 AMLO 5 → 10                      28.8/9.9                                              26.2/9.0
   Verpooten^[@C51]^             o, prospective         759            26                 150 → 300                                  25.1/11.3                                                                              
   Sowers^[@C65]^                Meta-analysis          1035           8--12              150                                        Placebo                          12.7/7.8                                              6.8/5.7
                                                                                          300                                                                         15.2/11.6                                             
   Zeymer^[@C50]^                o, prospective         4242           52                 150 → 300                                  ACEi/ARB                         18.2/7.7                                              14.7/6.5
                                                                                                                                     Non ACEi/ARB                                                                           14.2/6.3
   Braun-Dulleaus^[@C66]^        r, db, c, mc           219            8                  150 → 300 + Am 5 → 10                      AMLO 5 → 10                      34.4/15.2                                             30.5/12.3
  **Metabolic syndrome**                                                                                                                                                                                                    
   Weinberger^[@C43]^            r, c, db, mc           197            8                  150 → 300 + AMLO 5 → 10                    AMLO 5 → 10                      36.4/15.0                                             28.5/10.5
   Krone^[@C41]^                 r, c, db               141            12                 300                                        Irbesartan 300                   13.8/7.1                                              5.8/2.8
   White^[@C67]^                 Meta-analysis          2903           8--12              150                                        Placebo                          13.3/10.4                                             5.1/5.8
                                                                                          300                                                                         14.8/11.3                                             
   Lacourciere^[@C68]^           r, db, mc, c           613            8                  ALIS 300 + AMLO 10 + HCT 25                ALIS 300 + AMLO 10               36.2/20.0                                             28.9/16.9
                                                                                                                                     ALIS 300 + HCT 25                                                                      26.6/13.9
                                                                                                                                     AMLO 10 + HCT 25                                                                       29.7/16.5
   Ferdinand^[@C44]^             r, db, mc, c           284            8                  ALIS 300 + AMLO 10                         ALIS 300 + AMLO 10 + HCT 25      28.2/11.9                                             34.9/14.9
   Gradman^[@C42]^               Pooled                 166 238        8 \-- 12           150 300                                    Placebo                          15.0/11.4 15.1/11.7                                   5.0/5.9

Δ, difference; c, (active) controlled; db, double blind; HCT, hydrochlorothiazide; mc, multicenter; r, randomized; o, open; pc, placebo controlled; ACEI, angiotensin converting enzyme inhibitor; ALIS, aliskiren; AMLO, amlodipine; ARB, angiotensin receptor blocker; HCT, hydrochlorothiazide; VAL, valsartan.

→ indicates titration step (e.g. 150 → 300: from 150 mg/day to 300 mg/day).

Aliskiren and amlodipine have similarly long half-lives (aliskiren 40 h and amlodipine 30--50 h), which allows constant BP reduction throughout the entire dosing interval^[@C17]^ and beyond^[@C18]^. Besides complimentary mechanisms of action, aliskiren is capable to compensatorily down-regulate the rise in plasma renin activity following the addition of amlodipine^[@C21]^. The fixed combination of the two drugs (Rasilamlo) was investigated in a factorial study^[@C22]^, a long-term study^[@C23]^ and in add-on studies in patients not adequately responding to the monotherapy^[@C24],[@C25]^, which led to the approval of the SPC aliskiren/amlodipine^[@C26]^.

In the present post-hoc analysis of a previously published prospective non-randomized study^[@C27]^ we aimed to investigate the BP lowering effect of the SPC aliskiren/amlodipine in special patient groups with hypertension that typically present in everyday practice and may pose a particular challenge to treating physicians owing to comorbidity, comedication or complexity of the disease: patients of advanced age, high body mass index (BMI) (overweight, obesity), with metabolic risk factors and/or with DM.

Patients and methods {#S6}
====================

Study design {#S0006-S2001}
------------

The AWESOME study (Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker Plus Amlodipine) was performed between May and October 2010 as a multicenter, open-label, non-randomized single-arm study in 38 centers in Germany. The study was approved by the ethics committee of the State Chamber of Physicians in Saxony in Dresden and the responsible health authority (BfArM, Federal Institute for Drugs and Medical Devices). All patients provided written informed consent prior to inclusion in the study. The study was conducted according to the ethical principles of the Declaration of Helsinki. It was registered in the ClinicalTrials.gov database under NCT01113047 and in EudraCT under 2009-016693-33.

The study consisted of three phases, as shown in [Figure 1](#F1){ref-type="fig"}: after wash out, patients with mean sitting diastolic blood pressure (msDBP) 100--109 mmHg and mean sitting systolic blood pressure (msSBP) 160--179 mmHg at visit 3 (baseline) were included into a 4-week treatment phase 1 with forced titration to the SPC olmesartan 40 mg/amlodipine 10 mg; in non-responders (msDBP at trough ≥90 mmHg) this was followed by a subsequent 4-week treatment phase 2 with the SPC aliskiren 300 mg/amlodipine 10 mg once daily. This period was followed in non-responders (msDBP ≥90 mmHg and/or msSBP ≥140 mmHg at trough) by an optional 4-week extension with the SPC aliskiren 300 mg/amlodipine 10 mg/HCT 12.5 mg once daily. The aliskiren/amlodipine and aliskiren/amlodipine/HCT combinations were investigational formulations manufactured by Novartis for this study, whereas the olmesartan/amlodipine film tablets used were marketed products. The first 60 patients who were eligible and agreed to participate were included in the extension (results reported previously)^[@C27]^. Study drugs were to be taken orally in the morning. Compliance was assessed by pill count.

![Study design. \*Visit 2 was performed only in patients with previous antihypertensive therapy. \*\*Patients with an office mean sitting DBP\<90 mmHg at an unscheduled visit after visit 4 or at visit 5 were discontinued from the study. Dotted box highlights study phase from which data were analyzed for this paper.](ijda-2-1.01){#F1}

Patients {#S0006-S2002}
--------

Male and female patients aged ≥18 years with uncomplicated moderate essential hypertension as defined above were eligible for participation. Patients were excluded from the core study, if they presented with DBP ≥110 mmHg or SBP ≥180 mmHg at any time between visit 1 and baseline, or if they could not discontinue all antihypertensive medication safely for a period of up to 2 weeks.

Further important exclusion criteria comprised: controlled BP levels on current antihypertensive medication (DBP \<90 mmHg and SBP \<140 mmHg) at visit 1; known hypertensive retinopathy; heart failure in NYHA II--IV; secondary hypertension; refractory angina pectoris; significant hepatic or renal disease; DM \[type 1 or poorly controlled type 2, defined as a fasting blood glucose \>200 mg/dL (\>11.1 mmol/L)\]; second- or third-degree heart block without a pacemaker; significant arrhythmia or valvular heart disease; history of transient ischemic attack, stroke, hypertensive encephalopathy, myocardial infarction; contraindications for the study medication, and use of concomitant medications known to significantly affect the metabolism of the study drug or BP, pregnant or breast feeding women. Main exclusion criteria for the extension study were premature discontinuation during the core study, hypersensitivity or contraindications to diuretics, in particular to HCT.

Efficacy and safety parameters {#S0006-S2003}
------------------------------

The primary efficacy parameter of this trial was the change in trough msDBP between visit 5 (start of treatment phase 2) and visit 6 (end of treatment phase 2), and in addition further BP parameters were assessed (including changes in SBP, responder rates, etc.) as well as safety and tolerability. BP was recorded using a calibrated standard sphygmomanometer and appropriate size cuff, in accordance with the 2005 AHA Committee Report on blood pressure measurement^[@C28]^. BP values were measured three times at each visit, and the mean of all three sitting measurements recorded.

Patient aged ≥65 years were defined as elderly. The diagnosis DM in these hypertensive patients was according to physician's individual assessment. Overweight was defined as BMI 25.0--29.9 kg/m^2^, obesity as BMI ≥30 kg/m^2^. The condition 'at least one metabolic risk factor' was present, if serum glucose was ≥5.56 mmol/l, LDL cholesterol ≥4.16 mmol/l, or triglycerides were ≥2.28 mmol/l.

Safety and tolerability {#S0006-S2004}
-----------------------

The safety information included frequency of adverse events (AE), results of physical examinations, data on body weight, and laboratory evaluations. Vital signs were assessed as part of the efficacy evaluations. All laboratory samples, obtained in a fasting state, were sent to a central laboratory for analysis.

Statistical analysis {#S0006-S2005}
--------------------

The safety population of the respective phase comprised the sample of all patients who took at least one dose of the study medication, the intention-to-treat population (ITT) of all patients from the safety population in phase 2 who had at least one evaluation of the primary efficacy parameter after visit 5 (baseline phase 2).

The present post-hoc analysis was performed in subgroups of ITT patients with certain diagnoses as provided by demographic criteria (elderly patients), physician diagnoses (DM) in the context of clinical and laboratory criteria (metabolic risk factors including obesity). Patients suitable for several subgroups were analyzed in all these groups. The main analysis was performed descriptively on the mean change in trough SBP/DBP between visit 5 and visit 6 (treatment phase 2). The interpretation of all secondary parameters was explorative.

Results {#S7}
=======

Patient flow {#S0007-S2001}
------------

A total of 439 patients were screened of which 97 were not eligible (e.g., BP criterion not fulfilled) and 342 patients were enrolled in phase 1. A total of 187 patients were switched to aliskiren 300 mg/amlodipine 10 mg at the beginning of phase 2. In that phase, 74 patients were overweight, 89 were obese, 69 were aged 65 years and above (elderly), and 132 had at least one metabolic risk factor (91 without DM and 41 with DM).

Baseline characteristics in the total cohort and in the subgroups are shown in [Table 2](#TB2){ref-type="table"}. With the exception of two patients, all were Caucasians, mean age overall was 60.5 years, and 58.3% of patients were male. Mean age was higher in the group of patients with DM (64 years), while the gender distribution did not vary much across subgroups.

###### 

Baseline characteristics in all 3 phases, including subgroups in phase 2.

  Parameter                Phase 1       Phase 2       Phase 3                                                                                            
  ------------------------ ------------- ------------- ------------- -------------- ------------- ------------- ------------- ------------- ------------- -------------
  Number of patients       342           187           74            89             132           91            41            118           69            65
  Age (years) mean (±SD)   60.4 (10.9)   60.5 (10.7)   60.9 (10.9)   59.4 (10.9)    60.7 (10.3)   59.2 (10.6)   64.0 (8.6)    54.3 (8.1)    71.1 (4.6)    60.8 (10.8)
  Gender -- *n* (%)                                                                                                                                       
   Male                    182 (53.2)    109 (58.3)    46 (62.2)     54 (60.7)      79 (59.8)     55 (60.4)     24 (58.5)     69 (58.5)     40 (58.0)     46 (70.8)
   Female                  160 (46.8)    78 (41.7)     28 (37.8)     35 (39.3)      53 (40.2)     36 (39.6)     17 (41.5)     49 (41.5)     29 (42.0)     19 (29.2)
  Race -- *n* (%)                                                                                                                                         
   Caucasian               340 (99.4)    185 (98.9)    73 (98.6)     88 (98.9)      132 (100)     91 (100)      41 (100)      116 (98.3)    69 (100.0)    64 (98.5)
   Black/other             2 (0.6)       2 (1.1)       1 (1.4)       1 (1.1)        0 (0.0)       0 (0.0)       0 (0.0)       2 (1.7)       0 (0.0)       1 (1.5)
  Weight (kg) mean (±SD)   88.5 (19.3)   90.6 (20.1)   82.5 (10.4)   103.4 (19.7)   90.4 (19.7)   87.8 (16.4)   96.3 (25.0)   94.4 (22.6)   84.0 (12.7)   91.1 (19.0)
  SBP (mmHg) mean (±SD)    166.6 (6.2)   167.9 (5.3)   167.9 (5.2)   167.1 (5.3)    168.3 (5.4)   168.0 (5.1)   168.9 (5.8)   166.8 (4.9)   169.7 (5.5)   168.3 (5.2)
  DBP (mmHg) mean (±SD)    103.1 (3.0)   103.6 (2.6)   103.5 (2.7)   103.4 (2.5)    103.7 (2.6)   103.8 (2.7)   103.6 (2.5)   103.6 (2.4)   103.6 (2.9)   103.3 (2.3)

BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; ITT, intent-to-treat; HCT, hydrochlorothiazide.

Met risk, at least one metabolic risk factor present; SBP, systolic blood pressure.

Values are means (SD, standard deviation), or percentages (*n* (%))

Blood pressure {#S0007-S2002}
--------------

SBP and DBP at the beginning of the treatment phases are displayed in [Table 2](#TB2){ref-type="table"}, bottom. Mean baseline BP at the beginning of phase 2 in the total patient cohort was 168/104 mmHg, and it was nearly identical in the various subgroups. SBP and DBP reduction at end of phase 2 was −5.1/−4.8 mmHg in the total cohort, −5.5/−5.1 in the elderly, −6.7/−5.5 in overweight patients, −4.2/−4.5 in obese patients, and −5.5/−4.8 mmHg in metabolic risk patients (−6.4/−4.7 without DM, −3.3/−5.0 with DM; [Figure 2](#F2){ref-type="fig"}).

![Blood pressure reduction on aliskiren/amlodipine in the total cohort (ITT population) and in subgroups in phase 2 (week 8 compared with week 4).](ijda-2-1.02){#F2}

Tolerability and safety {#S0007-S2003}
-----------------------

Overall, 19 patients (10.1%) in phase 2 experienced at least one AE. No deaths or serious adverse events occurred. The most frequently observed AEs were 'peripheral edema' in seven (3.7%) patients, 'edema' in three (1.6%) patients and 'eczema' in one (0.5%) patient. All other AEs occurred only in one or two patients at maximum. Changes in laboratory values generally were infrequent, in accordance with the known profiles of the drugs. Details have been reported elsewhere^[@C27]^. AE were not analyzed by subgroups in view of the low patient numbers.

Discussion {#S8}
==========

The present subgroup analysis shows that treatment with the aliskiren/amlodipine SPC achieves meaningful BP reductions in elderly or obese patients, in metabolic risk patients or DM patients. These BP reductions were in line with the BP reduction in the overall study population.

Such patients are frequent in everyday care, and they may present a particular challenge to treating physicians. In a cross-sectional point prevalence study of 45,000 unselected consecutive patients in a representative nationwide sample of primary care physicians in Germany (HYDRA), 28% had a BMI ≥30.0 kg/m^2^ ^[@C29]^. Overall prevalence of hypertension, defined as BP ≥140/90 mmHg or on antihypertensive medication, was 60.6%, in grade 1 obesity 72.9%, in grade 2 obesity 77.1%, and in grade 3 obesity 74.1%. The odds ratio for good BP control (\<140/90 mmHg) in diagnosed and treated patients was 0.8 in overweight patients compared with normal weight, 0.6 in grade 1, 0.5 in grade 2, and 0.7 in grade 3 obese patients^[@C29]^. While patients with overweight/obesity are not specifically considered in the current ESC hypertension guidelines, those with metabolic syndrome are. Although no implication is made that it is a pathogenetic entity, metabolic syndrome is specifically mentioned as it constitutes a cluster of risk factors often associated with high BP which markedly increases cardiovascular risk^[@C30]^. At least five definitions with slight or moderate deviations from each other have been proposed by international organizations or by expert groups^[@C30]^. In our study, a more general approach was chosen, as patients with at least one 'metabolic risk factor' were analyzed in the respective group.

With respect to age, in elderly patients with uncomplicated hypertension, treatment should be initiated gradually, while in those with higher risk, goal BP should be achieved more promptly, which favors initial combination therapy and quicker adjustment of doses^[@C5]^.

As high age, high BMI and metabolic problems including DM are highly prevalent, the aliskiren monotherapy and aliskiren/amlodipine combination studies have included substantial fractions of such patients and found conclusive and consistent effects on BP in the various subgroups ([Table 1](#TB1){ref-type="table"}).

In obese patients, aliskiren-based treatment was highly effective and well-tolerated in patients who failed first line-treatment with a thiazide^[@C36]^, and (with optional addition of amlodipine) had a substantially lower incidence of hypokalemia (1 vs. 14%) compared with thiazide-based therapy^[@C37]^. In the same study, aliskiren provided a stronger antihypertensive effect compared with HCT^[@C37]^. In the ATTAIN study, the aliskiren/HCT combination was more effective than ramipril^[@C38]^, and a subanalysis of an aliskiren/amlodipine combination study showed similar BP lowering in obese or non-obese patients^[@C39]^. Recently, Boschmann highlighted aliskiren\'s prolonged BP-lowering effect following discontinuation, and showed that the drug penetrates adipose and skeletal muscle tissue at levels that are apparently sufficient to reduce tissue RAS activity^[@C40]^.

With regard to patients with metabolic syndrome, the Krone *et al*. study suggested that aliskiren 300 mg may offer advantages to irbesartan 300 mg^[@C41]^. In the pooled analysis by Gradman *et al*. no differences in the BP lowering effects between women with or without metabolic syndrome were noted^[@C42]^. Weinberger *et al*. reported that the aliskiren/amlodipine combination was more effective than amlodipine monotherapy in African-Americans with obesity or metabolic syndrome^[@C43]^. In a subgroup analysis of the ASCENT study, the dual aliskiren/amlodipine combination was as effective as the triple aliskiren/amlodipine/HCT combination in lowering BP among high-risk US minority patients with cardiometabolic syndrome^[@C44]^.

In patients with DM, studies on aliskiren (alone or in combination with angiotensin receptor blockers) mainly focused on the assessment of antiproteinuric/nephroprotective effects rather than the antihypertensive effects^[@C45],[@C46]^. However, the studies by Uresin *et al*. (aliskiren vs. ramipril)^[@C47]^ and Townsend *et al*. (aliskiren/HCT vs. amlodipine)^[@C48]^ showed beneficial BP lowering effects of aliskiren in diabetic patients. Also, a pooled analysis of aliskiren depicted the same effect in diabetic versus non-diabetic patients^[@C49]^. Interestingly, prospective registry data from the 3A Registry and the DRIVER study supported this finding in unselected patients^[@C50],[@C51]^.

In elderly patients, aliskiren exposure is modestly increased^[@C52]^. A significant dose relationship for the BP lowering effect was found in the elderly, with no evidence of dose-related increases in adverse events^[@C53],[@C54]^. Compared with a ramipril-based regime, aliskiren lowered BP significantly stronger in elderly patients with systolic hypertension^[@C55]^. A substantial BP reduction over the long term has further been substantiated in the 3A Registry with 15,000 unselected patients^[@C56]^.

Overall, the present analyses of the various subgroups in the AWESOME study, taken together with evidence from the aliskiren/amlodipine study program and other randomized studies indicate that the use of the combination leads to comparable efficacy in various subgroups. This could facilitate clinical management of the diverse hypertensive population. The overall results of the study show that the switch of patients not adequately controlled by the SPC olmesartan 40 mg/amlodipine 10 mg once daily to aliskiren 300/amlodipine 10 mg benefits about one-third of patients (36.4%) that can be treated to target at the end of phase 2 (week 8). For non-normalizers in phase 2, the addition of a thiazide diuretic in a SPC further led to a significant reduction of SBP and DBP.

Some methodological limitations should be considered when interpreting the results of the present analysis. Patients could be part of more than one subgroup (populations were not mutually exclusive). An open-label study, in particular without a control arm, can be compromised by unknown bias of various types^[@C57]^. The multiple subgroup analyses were specified post-hoc and carried out descriptively, and performed to assess the consistency of a treatment effect among various patient characteristics. Thus, the typical problems of subgroup analyses (in particular multiplicity) do not apply here^[@C58]^. However, the sample size of the current study was low and the treatment duration limited. Larger and longer-term studies are needed for definitive conclusions. Also for the assessment of safety, much larger datasets are needed^[@C59]^.

Conclusion {#S9}
==========

The SPC aliskiren 300 mg/amlodipine 10 mg had consistent BP lowering effects in various subgroups of patients with stage 2 hypertension. The BP lowering effect was in line with the achieved BP lowering effect in the total population of this study, and with various reports of other randomized controlled trials on this combination.
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